

Ira J Fox

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5194425/publications.pdf>

Version: 2024-02-01

47
papers

5,706
citations

126708

33
h-index

223531

46
g-index

47
all docs

47
docs citations

47
times ranked

4850
citing authors

#	ARTICLE	IF	CITATIONS
1	Synthetic human livers for modeling metabolic diseases. <i>Current Opinion in Gastroenterology</i> , 2021, 37, 224-230.	1.0	2
2	Hepatocyte Nuclear Factor 4 alpha 2 Messenger RNA Reprograms Liver-Enriched Transcription Factors and Functional Proteins in End-Stage Cirrhotic Human Hepatocytes. <i>Hepatology Communications</i> , 2021, 5, 1911-1926.	2.0	7
3	Cellular Location of HNF4 α is Linked With Terminal Liver Failure in Humans. <i>Hepatology Communications</i> , 2020, 4, 859-875.	2.0	12
4	Assembly and Function of a Bioengineered Human Liver for Transplantation Generated Solely from Induced Pluripotent Stem Cells. <i>Cell Reports</i> , 2020, 31, 107711.	2.9	81
5	Generation of Human Fatty Livers Using Custom-Engineered Induced Pluripotent Stem Cells with Modifiable SIRT1 Metabolism. <i>Cell Metabolism</i> , 2019, 30, 385-401.e9.	7.2	75
6	Liver-Enriched transcription factor expression relates to chronic hepatic failure in humans. <i>Hepatology Communications</i> , 2018, 2, 582-594.	2.0	28
7	Host conditioning and rejection monitoring in hepatocyte transplantation in humans. <i>Journal of Hepatology</i> , 2017, 66, 987-1000.	1.8	99
8	Clinical Hepatocyte Transplantation: What Is Next?. <i>Current Transplantation Reports</i> , 2017, 4, 280-289.	0.9	28
9	Induced pluripotent stem cells model personalized variations in liver disease resulting from α -1-antitrypsin deficiency. <i>Hepatology</i> , 2015, 62, 147-157.	3.6	77
10	Amelioration of Hyperbilirubinemia in Gunn Rats after Transplantation of Human Induced Pluripotent Stem Cell-Derived Hepatocytes. <i>Stem Cell Reports</i> , 2015, 5, 22-30.	2.3	64
11	Resetting the transcription factor network reverses terminal chronic hepatic failure. <i>Journal of Clinical Investigation</i> , 2015, 125, 1533-1544.	3.9	89
12	A Multiscale Agent-Based in silico Model of Liver Fibrosis Progression. <i>Frontiers in Bioengineering and Biotechnology</i> , 2014, 2, 18.	2.0	45
13	Liver transplantation for pediatric metabolic disease. <i>Molecular Genetics and Metabolism</i> , 2014, 111, 418-427.	0.5	105
14	Use of differentiated pluripotent stem cells in replacement therapy for treating disease. <i>Science</i> , 2014, 345, 1247391.	6.0	243
15	Cell and tissue engineering for liver disease. <i>Science Translational Medicine</i> , 2014, 6, 245sr2.	5.8	247
16	Effects of edaravone, a radical scavenger, on hepatocyte transplantation. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2014, 21, 919-924.	1.4	11
17	A Nonhuman Primate Model of Human Radiation-Induced Venocclusive Liver Disease and Hepatocyte Injury. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 88, 404-411.	0.4	30
18	A switch in the source of ATP production and a loss in capacity to perform glycolysis are hallmarks of hepatocyte failure in advance liver disease. <i>Journal of Hepatology</i> , 2014, 60, 1203-1211.	1.8	99

#	ARTICLE	IF	CITATIONS
19	Rapid and Sensitive Assessment of Human Hepatocyte Functions. <i>Cell Transplantation</i> , 2014, 23, 1545-1556.	1.2	39
20	Hepatocyte Transplantation. <i>Gastroenterology and Hepatology</i> , 2014, 10, 594-6.	0.2	2
21	New potential cell source for hepatocyte transplantation: Discarded livers from metabolic disease liver transplants. <i>Stem Cell Research</i> , 2013, 11, 563-573.	0.3	53
22	Engineering liver tissue from induced pluripotent stem cells: A first step in generating new organs for transplantation?. <i>Hepatology</i> , 2013, 58, 2198-2201.	3.6	8
23	The microenvironment in hepatocyte regeneration and function in rats with advanced cirrhosis. <i>Hepatology</i> , 2012, 55, 1529-1539.	3.6	59
24	A Whole-Organ Regenerative Medicine Approach for Liver Replacement. <i>Tissue Engineering - Part C: Methods</i> , 2011, 17, 677-686.	1.1	280
25	Barriers to the successful treatment of liver disease by hepatocyte transplantation. <i>Journal of Hepatology</i> , 2010, 53, 769-774.	1.8	137
26	Hepatic irradiation augments engraftment of donor cells following hepatocyte transplantation. <i>Hepatology</i> , 2009, 49, 258-267.	3.6	113
27	Differentiation and Transplantation of Human Embryonic Stem Cellâ€‘Derived Hepatocytes. <i>Gastroenterology</i> , 2009, 136, 990-999.e4.	0.6	485
28	Differentiation of mouse embryonic stem cells to hepatocyte-like cells by co-culture with human liver nonparenchymal cell lines. <i>Nature Protocols</i> , 2007, 2, 347-356.	5.5	121
29	Reversal of mouse hepatic failure using an implanted liver-assist device containing ES cellâ€‘derived hepatocytes. <i>Nature Biotechnology</i> , 2006, 24, 1412-1419.	9.4	209
30	Hepatocyte transplantation. <i>American Journal of Transplantation</i> , 2004, 4, 7-13.	2.6	118
31	Hepatocyte transplantation. <i>Journal of Hepatology</i> , 2004, 40, 878-886.	1.8	164
32	HEPATO CYTE TRANSPLANTATION. <i>Transplantation</i> , 2004, 77, 1481-1486.	0.5	110
33	Isolated Hepatocyte Transplantation in an Infant With a Severe Urea Cycle Disorder. <i>Pediatrics</i> , 2003, 111, 1262-1267.	1.0	292
34	Induction of Chimerism in Mice Using Human MHC Class I-Mismatched Hoechst 33342 Side Population Donor Stem Cells. <i>Cell Transplantation</i> , 2002, 11, 779-785.	1.2	6
35	Transplantation into and inside the liver. <i>Hepatology</i> , 2002, 36, 249-251.	3.6	16
36	Treatment of Carbon Tetrachloride and Phenobarbital-Induced Chronic Liver Failure with Intrasplenic Hepatocyte Transplantation. <i>Cell Transplantation</i> , 2000, 9, 671-673.	1.2	29

#	ARTICLE	IF	CITATIONS
37	Hepatocyte transplantation in rats with decompensated cirrhosis. <i>Hepatology</i> , 2000, 31, 851-857.	3.6	127
38	Prevention of Acute Liver Failure in Rats with Reversibly Immortalized Human Hepatocytes. <i>Science</i> , 2000, 287, 1258-1262.	6.0	334
39	Hepatocyte Transplantation for the Treatment of Human Disease. <i>Seminars in Liver Disease</i> , 1999, 19, 39-48.	1.8	363
40	Immunochemical properties of anti-Gal alpha 1-3Gal antibodies after sensitization with xenogeneic tissues. <i>Journal of Clinical Immunology</i> , 1999, 19, 116-126.	2.0	38
41	Treatment of the Criglerâ€Najjar Syndrome Type I with Hepatocyte Transplantation. <i>New England Journal of Medicine</i> , 1998, 338, 1422-1427.	13.9	1,008
42	Morbidity in patients with posttransplant diabetes mellitus following orthotopic liver transplantation. <i>Liver Transplantation</i> , 1996, 2, 276-283.	1.9	50
43	Low incidence of intraspousal transmission of hepatitis C virus after liver transplantation. <i>Liver Transplantation</i> , 1995, 1, 358-361.	1.9	3
44	Conditional immortalization of Gunn rat hepatocytes: An <i>in vivo</i> model for evaluating methods for bilirubin-UDP-glucuronosyltransferase gene transfer. <i>Hepatology</i> , 1995, 21, 837-846.	3.6	44
45	Proton spectroscopy of brain glutamine in acute liver failure. <i>Hepatology</i> , 1995, 22, 69-74.	3.6	65
46	Aplastic anemia after liver transplantation for fulminant liver failure. <i>Hepatology</i> , 1994, 20, 813-818.	3.6	91
47	Experimental Therapies: Hepatocyte Transplantation, Gene Therapy, and Liver Assist Devices. , 0, , 2432-2448.		0